The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...

About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation ...

For example, Nurix Therapeutics (NASDAQ:NRIX) shareholders have done very well over the last year, with the share price soaring by 135%. But while the successes are well known, investors should ...

Nurix Therapeutics, Inc. has appointed John Northcott as its new chief commercial officer, bringing over 20 years of experience in biotechnology commercialization. His background includes ...

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...